For Immediate Release

BIOMARIN TO ACQUIRE DIMERIX'S US PARTNER, AMICUS THERAPEUTICS, FOR US$4.8 BILLION

- BioMarin has entered into a definitive agreement to acquire Dimerix's US commercial licensing partner, Amicus, for a total equity value of approximately US$4.8 billion (~AU$7.25 billion[1])
- Subject to the transaction completing, BioMarin's acquisition will include the Dimerix commercial licensing contract, including all rights and obligations currently held by Amicus

MELBOURNE, Australia, 22 December 2025: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, today confirmed that BioMarin Pharmaceutical (NASDAQ: BMRN) has entered into a definitive agreement to acquire it's US commercial licensing partner, Amicus Therapeutics (NASDAQ: FOLD), in an all-cash transaction for a total equity value of approximately US$4.8 billion (~AU$7.25 billion[1]). See link Amicus and BioMarin Transaction for a copy of the transaction announcement.

Upon closing of the transaction, BioMarin's acquisition will include the Dimerix commercial licensing contract, including all rights and obligations currently held by Amicus.[2] The commercial licensing agreement remains in full force and effect. Until the closing of the transaction, Amicus and Dimerix will continue to collaborate on planning for DMX-200 in the U.S.

Under the commercial licensing Agreement between Dimerix and Amicus, Dimerix remains eligible to receive up to US$590 million (~AU$940 million[3]) in upfront, development and sales milestone payments, plus royalties in relation to its US licencing deal:

- Received US$30 million (~AU$48 million) on execution in May 2025[4]
- Up to US$75 million (~AU$119 million[3]) in potential development milestones
- US$35 million (~AU$56 million[3]) on first sale of DMX-200
- Up to $410 million (~AU$653 million[3]) in potential sales milestones
- US$40 million (~AU$64 million[3]) in potential future indications milestone
- Tiered low-teen to low-twenties royalties on net sales

The licence deals with territories outside the US remain unaffected: i.e. the license deal with Advanz Pharma (announced October 2023), Taiba (announced May 2024), and Fuso (announced 7 January 2025):

- Collectively, the four license deals provide up to ~AU$1.4 billion[5] in total upfront payments and potential milestone payments, plus royalties on net sales
- Over AU$65 million in total payments received to date[5]

Dimerix remains well positioned to continue focussing on advancing the ACTION3 Phase 3 clinical trial, as well as licensing opportunities with potential partners in territories not already licensed.

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. info@dimerix.com

"We are pleased to see such strong commercial interest in the rare disease space. BioMarin is a patient-focused multi-national rare disease company with a proven track record of navigating rare disease commercialisation. BioMarin have experience with global approvals, reimbursement strategies, in-house manufacturing, and have a strong and diverse rare disease portfolio. This transaction is fantastic news for patients with rare diseases, including FSGS, who currently have a poor prognosis and very limited treatment options. Collectively, we could deliver potential new life-changing therapies to patients faster and more efficiently. We look forward to collaborating with the BioMarin team in due course on the ongoing development and commercialisation of DMX-200."

Dr Nina Webster, CEO & Managing Director, Dimerix

About ACTION3 FSGS CLINICAL STUDY FSGS Phase 3 Study

The ACTION3 Phase 3 study is a pivotal Phase 3, multi-centre, randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of a blood pressure medication known as an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients are then randomised to receive either DMX-200 (120 mg capsule, twice daily) or placebo for a 2-year treatment period. The single Phase 3 trial in FSGS patients is designed to capture evidence of proteinuria reduction and kidney function (eGFR slope) during the trial, aimed at generating sufficient evidence to support marketing approval.

Further information about the study can be found on ClinicalTrials.gov (Study Identifier: NCT05183646) or Australian New Zealand Clinical Trials Registry (ANZCTR) (Study Identifier ACTRN12622000066785).

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Jane Lowe
IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au

Follow Dimerix on **LinkedIn** and **X**

Authorised for lodgement by the Board of Dimerix

—END—

About Dimerix Limited

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focused on developing its proprietary Phase 3 product candidate DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) kidney disease. DMX-200 was identified using Dimerix' proprietary assay,

Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform, enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. For more information, please visit the company's website at www.dimerix.com and follow on X and LinkedIn.

About DMX-200

DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to Orphan Drug Designation granted by the FDA in the United States.

About FSGS

FSGS is a rare, serious kidney disorder characterised by progressive scarring (sclerosis) in parts of the glomeruli—the kidney's filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. FSGS is increasingly understood to have an inflammatory component, with monocyte and macrophage activation contributing to glomerular injury. In the United States, more than 40,000 people are estimated to be living with FSGS, including both adults and children.[6] There are no therapies specifically approved for FSGS in the U.S., and disease management relies on non-specific immunosuppressive and supportive therapies. In patients with progressive or treatment-resistant FSGS, the average time from diagnosis to end-stage kidney disease can be as short as five years. Even among those who undergo kidney transplantation, disease recurrence occurs in up to 60% of cases,[7] underscoring the urgent need for new, disease-modifying treatments.

Dimerix Forward Looking Statement

This release includes forward-looking statements that are subject to risks and uncertainties. Although management believes that the expectations reflected in the forward-looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, along with those factors outlined in the most recent Dimerix Limited Annual Report.

References

1 *Based on exchange rate of 1 USD = 1.5112 AUD as at 20 December 2025*
2 *See SEC filing of redacted agreement at: Amicus 10-Q July 2025*
3 *Based on 30 day Wall Street Journal average exchange rate of 1 USD = 1.5924 AUD from 28 March - 28 April 2025*
4 *ASX release 06 May 2025*
5 *Based on XE exchange rates & further terms outlined in ASX Announcements on 5 October 2023, 27 May 2024, 07 January 2025, and 01 May 2025;*
6 *Nephcure FSGS Facts (https://nephcure.org/)*
7 *Front. Immunol., (July 2019) | https://doi.org/10.3389/fimmu.2019.01669*